<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082209</url>
  </required_header>
  <id_info>
    <org_study_id>M15-913</org_study_id>
    <secondary_id>2016-003887-37</secondary_id>
    <nct_id>NCT03082209</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies</brief_title>
  <official_title>An Open-Label, Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously-Treated Solid Tumors and Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose&#xD;
      (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and&#xD;
      pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid&#xD;
      tumors or hematologic malignancies.&#xD;
&#xD;
      Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC&#xD;
      who have received one prior line of therapy is open for enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">February 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>The MTD and/or RP2D of ABBV-621 will be determined during the dose escalation phase of the study of ABBV-621</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum/plasma concentration time curve (AUC) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Area under the serum/plasma concentration time curve (AUC) of ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum/plasma concentration time curve (AUC) of Venetoclax</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Area under the serum/plasma concentration time curve (AUC) of venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Maximum observed serum concentration (Cmax) of ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of Venetoclax</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Maximum observed serum concentration (Cmax) of venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Time to Cmax (Tmax) of ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of Venetoclax</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Time to Cmax (Tmax) of ventoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination rate constant (β) for ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination rate constant (β) for ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination rate constant (β) for Venetoclax</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination rate constant (β) for venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2) of ABBV-621 in Plasma</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination half-life (t1/2) for ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2) of Venetoclax in Plasma</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination half-life (t1/2) for venetoclax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcF Change from Baseline</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>QT interval measurement corrected by Fridericia's formula (QTcF) mean change from baseline by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 42 days after first day of study drug administration or 14 days after bone marrow biopsy showing &lt; 5% blast count (whichever is later)</time_frame>
    <description>Dose limiting toxicities for dose escalation purposes will be determined on events that occur during the first 21-day cycle (with protocol specified exceptions for AML participants).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with KRAS-mutant CRC are administered with ABBV-621 in combination with bevacizumab plus FOLFIRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy combination: ABBV-621+FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with RAS-mutant CRC who have received one prior line of therapy will be administered ABBV-621 in combination FOLFIRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization: ABBV-621 Monotherapy for AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization for Pancreatic Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization for KRAS-mutant CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-621</intervention_name>
    <description>Intravenous (IV)</description>
    <arm_group_label>Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab</arm_group_label>
    <arm_group_label>Chemotherapy combination: ABBV-621+FOLFIRI</arm_group_label>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Optimization for KRAS-mutant CRC</arm_group_label>
    <arm_group_label>Dose Optimization for Pancreatic Cancer</arm_group_label>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for AML</arm_group_label>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <arm_group_label>Dose Optimization: ABBV-621 Monotherapy for AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet, oral</description>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for AML</arm_group_label>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab</arm_group_label>
    <arm_group_label>Chemotherapy combination: ABBV-621+FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid&#xD;
             leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any subtype for Dose&#xD;
             Escalation but is limited to diffuse large B-cell lymphoma (DLBCL) for those enrolled&#xD;
             to the cohort evaluating the combination of ABBV-621 and venetoclax. Participants in&#xD;
             the Dose Optimization solid tumor cohorts must have either colorectal cancer with&#xD;
             documented KRAS mutations (as determined by local testing), or pancreatic cancer&#xD;
             (irrespective of mutational status). Participants in the chemotherapy combination&#xD;
             cohorts must have metastatic or advanced unresectable colorectal cancer with&#xD;
             documented RAS mutations (as determined by local testing).&#xD;
&#xD;
          -  Participant in dose escalation or dose optimization cohort must have received at least&#xD;
             one prior systemic therapy, and must have relapsed or progressed after, or failed to&#xD;
             respond to any/all available effective therapy or therapies.&#xD;
&#xD;
          -  Participant in chemotherapy cohorts with CRC must have progressed after or failed to&#xD;
             respond to initial systemic therapy.&#xD;
&#xD;
          -  Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST]&#xD;
             1.1 for those with solid tumors; by Lugano classification for those with NHL), except&#xD;
             those with AML, who must have histologically confirmed relapsed or refractory disease.&#xD;
&#xD;
          -  Must agree to provide the following samples for biomarker analysis:&#xD;
&#xD;
               -  All participants: archived tumor tissue (if available).&#xD;
&#xD;
               -  Participants in Dose Optimization (excluding AML): pre- and on-treatment fresh&#xD;
                  tissue biopsies. (Note: fresh tissue biopsies will be optional for participants&#xD;
                  with solid tumor or NHL in Dose Escalation and will be collected only if consent&#xD;
                  is provided)&#xD;
&#xD;
               -  All participants with AML: pre- and on-treatment bone marrow aspirates (BMA)&#xD;
&#xD;
               -  Participants in chemotherapy combination cohorts: participants must provide a&#xD;
                  fresh biopsy if an archival biopsy is not available&#xD;
&#xD;
          -  Participant in chemotherapy cohorts with CRC must have confirmed RAS mutation&#xD;
&#xD;
          -  Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2.&#xD;
             Participants in chemotherapy combination cohorts must have ECOG Performance Score of 0&#xD;
             - 1.&#xD;
&#xD;
          -  Must have adequate hematologic, renal and hepatic function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with history of brain metastases who have not shown clinical and&#xD;
             radiographic stable disease for at least 28 days after definitive therapy. In&#xD;
             addition, any AML participant identified through cerebrospinal fluid (CSF) analysis,&#xD;
             as having active central nervous system (CNS) disease, will be excluded.&#xD;
&#xD;
          -  Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or&#xD;
             hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater.&#xD;
&#xD;
          -  Receipt of any systemic anti-cancer agent, including investigational anti-cancer&#xD;
             products, within 21 days prior to study drug administration or 3 half-lives, whichever&#xD;
             is longer.&#xD;
&#xD;
          -  Participant with a history of cirrhosis or other indication of significant possible&#xD;
             hepatic dysfunction. Note: Those with non-alcoholic steatohepatitis (NASH) should be&#xD;
             discussed with the AbbVie TA MD before enrollment.&#xD;
&#xD;
          -  Participant with a positive diagnosis of hepatitis A, B, or C.&#xD;
&#xD;
          -  Dose Optimization combination cohorts only: Prior receipt, at any time, of a BCL-2&#xD;
             inhibitor&#xD;
&#xD;
          -  Dose Optimization combination cohorts only: Participant has received strong or&#xD;
             moderate CYP3A inhibitors or inducers within 7 days prior to the initiation of study&#xD;
             treatment.&#xD;
&#xD;
          -  Dose Optimization combination cohorts only: Participant has malabsorption syndrome or&#xD;
             other condition that precludes enteral route of administration.&#xD;
&#xD;
          -  Dose Optimization combination cohorts only: Participant has promyelocytic leukemia&#xD;
             (M3).&#xD;
&#xD;
          -  CRC chemotherapy cohort only: Participant with minor surgical procedures, such as fine&#xD;
             needle aspirations or core biopsies, within 7 days prior to first dose of study drug&#xD;
             are excluded.&#xD;
&#xD;
          -  Participants in CRC chemotherapy combination cohort only: cardiomyopathy,&#xD;
             coronary/peripheral artery bypass graft, aneurysm or aneurysm repair, angioplasty,&#xD;
             pulmonary hypertension, cerebrovascular accident or transient ischemic attack, within&#xD;
             1 year of first dose of study drug.&#xD;
&#xD;
          -  Chemotherapy combination CRC participants only: Prior receipt of an irinotecan-based&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Chemotherapy combination CRC participants only: Disease progression within 3-months of&#xD;
             initiating first-line therapy.&#xD;
&#xD;
          -  Chemotherapy combination CRC participants only: history of Gilbert's syndrome or&#xD;
             UG1T1A1 genotypes.&#xD;
&#xD;
          -  Chemotherapy combination with bevacizumab participants only: clinically significant&#xD;
             conditions that may place the participant at higher risk with anti-angiogenic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University /ID# 158029</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center /ID# 158030</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hosp /ID# 171221</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Michigan Med Ctr /ID# 207134</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital /ID# 171157</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center /ID# 215000</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center /ID# 202187</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Oncology /ID# 214981</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090-1243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics /ID# 160574</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin /ID# 171152</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 160596</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital /ID# 200681</name>
      <address>
        <city>Yamagata-shi</city>
        <state>Yamagata</state>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum /ID# 160869</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen /ID# 169748</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum /ID# 214935</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht /ID# 169747</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron /ID# 170809</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz /ID# 200106</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro /ID# 165136</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Cancer</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>acute myeloid leukemia (AML)</keyword>
  <keyword>colorectal cancer (CRC)</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma (DLBCL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

